DAEWOONG PHARMA Termination of Southeast Asia pitavastatin supply contract, KRW 69,227,120,771
DAEWOONG PHARMA· Single Sales/Supply Contract
DAI summary · Not investment advice
The Southeast Asia pitavastatin calcium tablet supply contract with ABBOTT was terminated, with a termination amount of KRW 69.2 billion, 8.24% of revenue.
Termination amount
KRW 69.2 billion
Key facts
- Terminated contract
- Export supply contract for Daewoong Pitavastatin Calcium tablets in Southeast Asia
- Recent revenue
- KRW 839.7 billionBased on 2015 consolidated financial statements
- % of revenue
- 8.24%
- Counterparty
- ABBOTT PRODUCTS OPERATIONS AG (Switzerland)
- Contract period
- Nov 2, 2016 – Nov 2, 2026
- Reason for termination
- Termination by mutual agreement due to changes in the business environment
- Termination date
- Feb 28, 2024
- Original contract disclosure date
- Nov 3, 2016
Show Korean comments
Comments
No comments yet
Comments from shareholders will appear here.
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist